Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

The eu market for bioanalysis


Published on

Bioanalytical market, bioanalysis, pharmaceutical development, contract services

  • Be the first to comment

  • Be the first to like this

The eu market for bioanalysis

  1. 1. PARIOFORMA Summary Report – October 2003PARIOFORMA LTD55 Princes GateExhibition RoadLondon SW7 2PNUnited KingdomTel: +44 (0) 20 7225
  2. 2. PARIOFORMA PHARMACEUTICAL R&D EXPENDITURE IN EUROPE AND USA 35000 30000 Millions Euros 25000 20000 US 15000 EU 10000 5000 0 1990 2000 2001 2002eFIGURE  The European pharmaceutical industry invested 18.9 billion Euros in R&D in 2001, and was projected to spend 19.8 billion Euros in 2002.  This sum covers all R&D spending within EFPIA countries by national and foreign companies.  However, despite increasing R&D spending in Europe it should be noted that Europe is gradually losing ground to the US as a locus of innovation. Between 1990 and 2002, R&D investment in United States rose more than fivefold, while in Europe it only grew 2.5 times. Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
  3. 3. PARIOFORMA Amount spent in each country by national and foreign companies 6000 1999 2000 2001 5000 Euros Millions 4000 3000 2000 1000 0 UK Finland Italy Spain France Norway Belgium Germany Ireland Denmark Netherlands Sweden SwitzerlandFIGURE 2 Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
  4. 4. PARIOFORMA By location of mother company 120 100 97 Number of chemical entities 90 80 77 66 68 Europe 63 61 United States 60 52 Japan Others 40 29 20 5 6 4FIGURE 3 0 1988-1992 1993-1997 1998-2002 Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
  5. 5. PARIOFORMA A major driving force behind the growth of the European Biotech industry was the flow of money into dedicated mutual funds in the latter part of the 1990’s up until 2000. In addition, countries such as The Netherlands and Germany were at the forefront of integrating state and private capital to support the life sciences industry – this had the effecting of initiating many new Biotech start-ups, notably in Germany who still lead Europe in terms of the number of companies – see figure 4. However, the impressive stock performances witnessed by European companies over this period was not sustainable. After a decade of 30-40% year on year growth in revenues, the European biotech sector stalled in 2002. The UK remains the dominant player with 43% of total market capitalization (€9.4 billion) and 37% (€2.9 billion) of revenues. The current hostile financing environment is forcing companies to radically rethink their strategies, and further fall-out in the sector can be expected over the coming twelve months. However this is a cycle that has been experienced several times already in the US and will result in a stronger and more robust industry in Europe. However, it should be noted that the number of profitable biotech companies is increasing and the average loss per public company has halved over the past 4 years to €7 million. Europes public biotech companies now have 53 products in phase III clinical trials. Hence despite the harsh environment companies are continuing to develop innovative products and a potential tidal wave of product successes is building up, which could transform the industry. Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
  6. 6. PARIOFORMA 400 13 Private Public 350 46 300 Number of Companies 250 6 200 9 347 2 150 285 5 233 100 3 170 1 5 1 147 124 1 50 82 2 75 70 68 3 50 33 18 0 Israel Belgium Italy France Germany Denmark Ireland Netherlands Finland UK Norway Sweden SwitzerlandFIGURE 4 Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
  7. 7. PARIOFORMA 10 9 8 7 Billions Euros 6 5 4 3 2 1 0 Industry market capitalisation UK Switzerland Netherlands Revenues Ireland France GermanyFIGURE 5 Source: Ernst & Young Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
  8. 8. PARIOFORMAParioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
  9. 9. PARIOFORMAFIGURE 7 500 450 400 350 Millions Euros 300 US 250 EU 200 150 100 50 0 2000 2001 2002e 2003e 2004e 2005e Source: RM Consulting, published data PhRMA, E & Y, Scrip, Pharmaceutical Compendium: CMR International Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
  10. 10. PARIOFORMA Figure 7 depicts the market forecasts for the North American and European bioanalytical market – development and discovery support. It shows modest, but sustained growth over the next few years; however, calculations assumed a constant US vs. EU split of R&D expenditure over this period1. Given the current trend towards the US as a locus of innovation; figures might be biased slightly more in favour of the US over time. Market analysis revealed that the key drivers for market value are: ◦ the volume of new business arising, due to new candidates entering development – there are an average 3,405 drugs2 in active trials worldwide with an estimated 1,362 candidates in trials 3 in Europe; ◦ increased outsourced volumes from medium sized Pharma and Biotechs – these companies are traditional outsourcers; ◦ higher sample prices for increased complexity of biomolecule assays; ◦ increased range of possible assays at premium prices – biomarkers, metabolite profiling, etc. The underlying market growth rate is positive - bioanalysis remains an attractive business.1 The R&D split for the year 2001 (EFPIA, PhRMA- Pharmaceutical R&D Expenditure in Europe and the USA): Europe: 41%; USA : 59%.2 Average number of Adis R&D Insight; IMS R&D Focus; Pharmaprojects.3 RM estimate based on the ratio of new entities by geographical region. Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
  11. 11. PARIOFORMA Bioanalytical buying behaviour can be viewed as a factor of company size, company “attitude” and the stage of development. “Attitude,” or the propensity to outsource, is both a function of company size and company culture. Geographical location impacts on a company’s social, cultural and economic heritages. Analysis of the European bioanalytical market highlighted some geographical trends: ◦ Particularly in continental Europe there can be very significant “social” costs that a company must pay for each employee; it is also a highly regulated employment market – this combined with low cost labor market gives rise to the tendency for more to be done in-house in parts of continental Europe than in the US; ◦ There is a trend to use European phase I units (notably in the UK) to avoid regulatory IND submissions – however, phase II often returns to the US in preparation for FDA registration; ◦ Within Europe, the issue of language barriers can add further complexity, people preferring to deal with a service supplier in their mother-tongue. There is also the concept of keeping work within national boundaries – e.g. French companies prefer to deal with French vendors; ◦ Additionally, the buying process tends to be more formalized for US based companies who have well developed procurement procedures – such processes tend to be more embryonic for European based pharmacos. Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
  12. 12. PARIOFORMA Market research indicates that the European bioanalytical business lags behind the US by as much as two years in terms of market development. The European business is also far more fragmented than in North America and is characterized by: ◦ several new entrants in last 2 years – e.g. York Bioanalysis, Xendo Labs; ◦ a great many small labs with 3 – 6 LC/MS machines; ◦ “stand-alone” labs, as opposed to full service CROs, offering a suite of bioanalytical services including LC- MS/MS and immunoassays; ◦ no dominant player – MDS, unlike in the US, is not a strong player. The competitive situation in Europe is not as intense as in the US, and most labs are predicting growth in middle and upper teens. This is because they are not yet under the same degree of price pressure as in the US; in part because their prices are already much lower1, but also because “mid-sized” European Pharma companies have continued to maintain or grow their outsourcing in contrast to US “Big Pharma”. European Pharma companies also feel that they are getting “good value” from the contract labs and are less concerned about price than their US counterparts. 1 See Appendix Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
  13. 13. PARIOFORMA The bioanalytical lab market currently shows no signs of concentrating, with no “lab-lab” mergers. Instead the trend has been to acquire or merge with complementary organisations e.g. PPDI + MRLI, Inveresk + ClinTrials, Icon + Medeval, AAI + MTRA; Cephac + ITEC Pharmacology; or for new entrants to buy their way in e.g. Parexel + CEMAF. These “complimentary” mergers link the bioanalytical services of one company to the clinical services of another with the aim of improving business lead generation and more importantly the continuity of business from one phase to another. Europe has also been the focus for expansion for many US labs – the UK in particular, for example: ◦ ABC Laboratories – N. Ireland (now acquired by CSS Analytical); ◦ Advion Biosciences – Norwich, England; ◦ BAS – Congleton, England; ◦ BioReliance – Scotland; ◦ CentaLabs – Cambs; England. Other well-known bioanalytical names in Europe include: ◦ Covance – Harrogate, England; ◦ AAI – Neu-Ulm, Germany; ◦ MDS – Zurich, Switzerland; ◦ Quintiles – Scotland, Sweden; ◦ Inveresk – Scotland; Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
  14. 14. PARIOFORMA Despite the trend towards the US as a locus of innovation, Europe still exhibits healthy growth in terms of R&D spending – see figure 1. In the past 5 years, Europe in particular has experienced vigorous M&A activity in the pharmaceutical industry. A consequence of this has been much pipeline pruning with delays, postponements and even cancellations in clinical programs. The effects of this are still being felt - see figure 3. However, worldwide drug pipelines are healthy with an estimated 1,362 candidates in active clinical trials in Europe, including 53 products in phase III originating from Europes public biotech companies. Europe can be divided into bioanalytical “hotspots” according to R&D spending – see figure 2: 1. UK; Decreasing 2. Germany; attractiveness on the basis of 3. France; R&D spending 4. Switzerland; 5. Scandinavia – Norway, Finland, Sweden, Denmark; 6. Benelux – The Netherlands, Belgium; 7. Italy; 8. Spain. Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
  15. 15. PARIOFORMA Germany still leads in Europe in terms of the number of Biotech companies – see figure 4. However, there is a widening divide in terms of revenues and market capitalisation – see figure 5. The UK remains the dominant Biotech player and therefore, provides the most attractive opportunity from a bioanalytical perspective. Not only are there a large number of Biotech companies themselves, but revenues are stronger – these companies are more likely to be able to afford and maintain clinical programs. This report would not be complete without mentioning the fact that Europe has a very mature generics industry that is facing a period of unprecedented growth - $82 billion worth of global blockbusters are set to face US patent expiry by 2007. Rising competition from Indian and Eastern European low cost generic providers will augment the pressure on margins, forcing Western players to add value through specialty generics and super generics. For some labs the generic market is an attractive business; but unlike the “research business” this area is highly price sensitive - prospective customers “shop around” for the cheapest option. It is particularly suitable for high volume players who can easily amortise the cost of assay development. Entering this market can require considerable investment. Proprietary assays are usually owned by the original customer, consequently a lab has to re-develop and validate an assay before it can claim ownership and sell on to a generics customer. The economics of the business suggest that it takes 2 – 3 customers to break into profit per assay developed. Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
  16. 16. PARIOFORMA Summary of Opportunities All three countries present an attractive opportunity for a bioanalytical business. The United Kingdom because it remains the main focus of R&D spending in Europe and continues to outpace the rest of Europe in this respect. It has the highest number of R&D bases and the most profitable Biotech industry in Europe. Employment laws are more favourable in the UK than in continental Europe; however, sales of a UK-based facility could be vulnerable to exchange rate fluctuations.United Kingdom Germany is also attractive from an R&D point of view. AAI is the dominant player and there are a number of local players – Germany has not been the focus of expansion for US-basedGermany labs as has the UK. Germany also leads Europe in the size and maturity of its genericsSwitzerland industry. For its size, Switzerland has a high density of R&D based companies and a high level of R&D spending. MDS is present but not dominant, and there are a number of well- established local players. A lab situated in either Germany or Switzerland is also well placed from a geographical point of view to serve customers in other parts of continental Europe. Attractive from an R&D spending point of view; but this market is heavily dominated by Aster Cephac and Parexel. Aside from these large players there are only a handful of smaller localFrance players. Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
  17. 17. PARIOFORMA Summary of Opportunities Sweden and Denmark dominate in terms of R&D spending. The region supports a large number of Biotech companies, led by Sweden, but BiotechScandinavia – revenues are very low in comparison to other countries in Europe.Norway, Sweden, In terms of suppliers, Quintiles has a small facility attached to a Phase I unit in Sweden – butFinland and this is not well advertised. There are a few local suppliers, again mainly in Sweden, and many sponsor companies traditionally outsource to other regions of Europe.Denmark Sales from a lab in this region would also be vulnerable to fluctuations in exchange rates. It is probably not an area that would attract bioanalytical business from other parts of Europe. Already many low cost labs present notably in The Netherlands where governmentBenelux – The investment helped initiate start ups in the life science sector.Netherlands and Many technical graduates at low cost and a highly regulated employment market – hence many R&D based companies find it more cost effective to conduct work in-house rather thanBelgium to outsource. Sponsor firms either conduct in-house bioanalysis or outsource to Northern EuropeanSouthern Europe – companies. Some very small local labs only.Italy & Spain Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
  18. 18. PARIOFORMA Summary of Opportunities The Czech and Slovak Republics, the Baltics, Poland, Hungary, and Slovenia will all be part of Europe as of May 2004. The domestic pharmaceutical industry in this region is dominated by the cheap local production of generic drugs. R&D bases of Western firms tend to conduct work in-house due to the low cost of skilled labor as well as outsourcing to Western European companies. The CEE is now fast becoming the preferred location for many clinical trials due to theCEE relatively lower costs per patient (in comparison to Western Europe) as well as the need to access treatment naive patients. A lab in this region [e.g. Czech Republic] could leverage the cheap skills base and the ease of communication with the rest of Europe. There are at present, no well known bioanalytical names in this region. Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
  19. 19. PARIOFORMAGEOGRAPHY Mid 1990s (US $) 2002 (US$) 2004/2005 US$USA} Average for Standard Assay $130 $70 $40USA } Range for Standard Assay $100 - 150 $60 - 80 $30 - 40Europe} Average for Standard $90 $63 $50AssayEurope} Range for Standard $84 - $98 $50 - 90 -AssaySource: RM estimates and analysis Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
  20. 20. PARIOFORMARM Consulting is now part of Parioforma Ltd., an independent business consultancyheadquartered in London, UK.Key benefits of working with Parioforma: Bespoke studies – tailored to client needs and timelines. LONDON OFFICE ASSOCIATE OFFICES Affordable research prices – makes your budgets go further. Intrix Corp, Darien Charles Rowlands USA High quality research – experienced science-based Connecticut Senior Partner team, all with post-graduate science and/ or MBA qualifications and with 10-25+ years experience in Life Eastern 55 Prince’s Gate IMRP, Moscow Science and High Technology industries. Europe Unique problem solving approach – the team is Exhibition Road highly specialised, but diverse in experience and London SW7 2PN Intrix Corp, São Brazil background, enabling analysis of problems from United Kingdom Paulo different perspectives. Tel: +44 (0) 7803 907577 Strategic Pointers – helps clients better understand Japan TRN, Tokyo the research and implications for their business. Practical implementable solutions – not just “over-clever analysis.”Our knowledge is extensive and experience Please dont hesitate to contact us for anbroad – please visit our website for a full informal discussion – either by telephone onlisting of all our services. +44 (0) 207 225 3538 or by email at: Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom